0001209191-17-059802.txt : 20171108 0001209191-17-059802.hdr.sgml : 20171108 20171108171456 ACCESSION NUMBER: 0001209191-17-059802 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171106 FILED AS OF DATE: 20171108 DATE AS OF CHANGE: 20171108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Laliberte Kevin CENTRAL INDEX KEY: 0001709417 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38135 FILM NUMBER: 171187500 MAIL ADDRESS: STREET 1: C/O DOVA PHARMACEUTICALS, INC. STREET 2: 240 LEIGH FARM ROAD, SUITE 245 CITY: DURHAM STATE: NC ZIP: 27707 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dova Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001685071 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813858961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2530 MERIDIAN PARKWAY STREET 2: SUITE 300 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919-806-4487 MAIL ADDRESS: STREET 1: 2530 MERIDIAN PARKWAY STREET 2: SUITE 300 CITY: DURHAM STATE: NC ZIP: 27713 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-11-06 0 0001685071 Dova Pharmaceuticals, Inc. DOVA 0001709417 Laliberte Kevin C/O DOVA PHARMACEUTICALS, INC. 240 LEIGH FARM ROAD, SUITE 245 DURHAM NC 27707 0 1 0 0 Sr. VP, Product Development Employee Stock Option (Right to Buy) 3.73 2017-11-06 4 A 0 24750 0.00 A 2027-03-27 Common Stock 24750 24750 D The Reporting Person was granted a stock option on March 28, 2017 (the "Date of Grant") providing for milestone vesting based on the Issuer's successful completion of two Phase IIIB/IV clinical trial protocols as determined and certified in writing by the Board of Directors (the "Board"). Such milestone was achieved on September 29, 2017 and certified by the Board on November 6, 2017. The exercise price of the option is the fair market value of the Issuer's Common Stock on the Date of Grant. The option shall vest over a period of four years as follows: (i) 25% of the total shares subject to the option shall vest on September 29, 2018, and (ii) the balance of the shares shall vest in a series of thirty-six (36) successive equal monthly installments beginning on October 29, 2018, subject to the Person's continuous service with the Issuer as of each such date. In addition, the option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock. /s/Jason Saxe, Attorney-in-Fact 2017-11-08